Compare US Global Jets ETF (JETS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs ResMed Inc. — how do they compare? US Global Jets ETF trades at $27.7 (market cap $878.48M), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 36.2× US Global Jets ETF's market cap, and ResMed Inc. pays a 1.17% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Global Jets ETF for 26 Days and ResMed Inc. for 51 Days on average.
| JETS | RMD | |
|---|---|---|
Market Cap | $878.48M | $31.78B |
Volume | 4,402,990 | 1,128,382 |
Sector | Sector/Thematic | Health |
52-Week High | $33.53 | $277.88 |
52-Week Low | $23.64 | $182.82 |
Typical Hold Time | 26 Days | 51 Days |
Enterprise Value | — | $31.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $27.67, down 1.53% with a bearish technical outlook. The ETF faces headwinds from rising fuel costs and geopolitical tensions impacting airline profitability. Recent news highlights underperformance versus aerospace/defense ETFs, with competitors like ARKX and ITA showing stronger returns. Technical indicators show oversold conditions on short-term RSI but overall bearish momentum from moving averages.
The outlook remains challenged by fuel price volatility and competitive pressure from alternative aviation ETFs. Near-term support at $27 could provide a technical floor, but sustained recovery requires easing of fuel cost pressures and improved airline earnings visibility. The ETF's concentration in pure airline operators increases sensitivity to industry-specific risks.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
